 San Diego, Calif, April 22, 2021 GLOBE NEWSWIRE -- Skye Bioscience, Inc. OTCQB: SKYE SKYE or the Company, a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, has established its Chemical, Manufacture and Controls CMC procedures for the production of THCVHS drug product suitable for Good Laboratory Practice GLP non-clinical research. This is a key step in advancing the Companys planned Phase 1 study for its lead drug candidate, THCVHS, a novel prodrug of THC for the treatment of glaucoma. 